MAKE AN
APPOINTMENT
Call
404-287-0123

GLP-1 Receptor Agonist Therapy for Weight Loss: Clinical Outcomes in Atlanta

GLP-1 receptor agonist therapy ranks among the most clinically validated pharmacological tools for chronic weight management, producing average body-weight reductions of 15% or more in landmark clinical trials. Age Well ATL physicians deploy this evidence base inside a supervised care model designed to replicate and sustain those outcomes for Atlanta patients. Realistic expectations about GLP-1 therapy results help patients commit to treatment with confidence and measurable goals.

What are GLP-1 receptor agonists and how do they produce weight loss?

GLP-1 receptor agonists are FDA-approved pharmacotherapy for chronic weight management in adults with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity. These medications mimic the endogenous glucagon-like peptide-1 hormone, suppressing appetite and slowing gastric emptying so patients eat less and lose weight.

GLP-1 receptor agonist therapy produces weight loss through slowing of gastric emptying and central appetite suppression via GLP-1 receptor activation, reducing caloric intake. According to a 2025 review in The American Journal of Medicine, these medications enhance glucose-dependent insulin secretion, inhibit glucagon release, and enhance satiety by acting on the central nervous system. Here is what that looks like in practice:

GLP-1 receptor agonists are available at varying dosages across the class. The treating physician selects and adjusts each patient’s dosage based on individual response and tolerability rather than applying a fixed protocol, and that personalization is a large part of why physician supervision matters with this therapy.

What do clinical trials show about GLP-1 therapy outcomes for weight loss?

Clinical trials show that GLP-1 receptor agonist therapy produces significant, sustained body-weight reduction compared with placebo, lowers the rate of major cardiovascular events, and improves blood sugar control. The SELECT trial supplies the largest outcome dataset in adults with obesity and established cardiovascular disease.

The SELECT trial enrolled 17,604 adults aged 45 or older with a BMI of 27 or greater, pre-existing cardiovascular disease, and no history of diabetes, and ran from October 2018 through June 2023, according to Cleveland Clinic (2023). SELECT trial participants achieved average body-weight reduction of approximately 15% compared to placebo, and the effect proved durable. At 208 weeks, the GLP-1 weight-loss therapy arm showed a mean body-weight reduction of 10.2% versus 1.5% with placebo, plus a 7.7 cm greater reduction in waist circumference, as Nature Medicine (2024) reports.

The SELECT trial also demonstrated a 20% reduction in major adverse cardiovascular events, defined as cardiovascular death, nonfatal heart attack, and stroke, according to the American College of Cardiology (2024) and Nature Medicine (2024). That finding establishes GLP-1 therapy as a dual-purpose cardiometabolic intervention rather than a weight-loss treatment alone. Participants across the GLP-1 trial program improved blood sugar levels as well, a result that carries particular weight for patients managing type 2 diabetes alongside obesity.

One caveat matters when reading these numbers. The roughly 15% average applies to a cohort in which every participant had established cardiovascular disease. Patients without cardiovascular comorbidity and patients with type 2 diabetes entered different trial cohorts with different baseline profiles, so citing 15% as a universal expectation overstates what a newly diagnosed, otherwise healthy patient should expect. Interpreting measurable weight loss outcomes on GLP-1 requires a physician to match the right cohort data to each patient’s own cardiovascular and metabolic profile.

Dual GIP/GLP-1 agonist therapy has been compared to GLP-1 receptor agonists in head-to-head trials. In SURMOUNT-5, the first direct comparison of the two incretin-based classes, dual GIP/GLP-1 agonist therapy produced a 20.2% mean body-weight reduction versus 13.7% with GLP-1 receptor agonist therapy at 72 weeks, according to the American College of Cardiology (2025). Both classes demonstrate meaningful clinical efficacy, and GLP-1 receptor agonists hold the longer, well-established safety record.

Across trial cohorts, GLP-1 receptor agonists consistently outperform older weight-loss pharmacotherapies, and most side effects remain manageable under physician supervision.

What are the safety risks and side effects patients should know before starting GLP-1 therapy?

GLP-1 receptor agonist side effects include nausea, vomiting, diarrhea, constipation, and abdominal pain, which peak during dose titration, plus rare serious events such as pancreatitis, kidney function changes, and depression that physician monitoring detects early.

According to a 2025 US Pharmacist review, gastrointestinal effects are the most common adverse effects of GLP-1 receptor agonists and dual GIP/GLP-1 agonist therapy. In the SURPASS and SURMOUNT trials, nausea affected up to 32% of participants, diarrhea 23%, vomiting 12%, and constipation 11%. These symptoms are dose-dependent, concentrate in the titration phase, and typically decrease after dose-titration adjustment as the body adapts.

Serious adverse events are uncommon, and each carries a recognizable warning sign:

Most patients who discontinue GLP-1 therapy stop within the first four to eight weeks, while doses are still escalating. Gradual dose escalation is the primary clinical tool for reducing GI severity, and a structured protocol managed by a physician materially reduces early dropout compared with unmonitored use. Age Well ATL follows this kind of structured dose-escalation protocol with every patient, adjusting the pace to how each person responds.

Physician supervision enables early detection of serious adverse events, including pancreatitis, kidney function changes, and psychiatric symptoms, through structured monitoring protocols. Scheduled check-ins, lab work, and symptom reviews catch problems while the problems are still small and reversible.

Injection site reactions such as redness or mild swelling are a minor but real concern. The Age Well ATL care team reviews proper injection technique with each patient, which reduces how often these reactions occur and how severe they feel.

How does Age Well ATL’s physician-supervised program translate clinical trial outcomes into real patient results?

Age Well ATL’s physician-supervised program applies individualized treatment plans that combine GLP-1 pharmacotherapy with lifestyle modification and regular monitoring to sustain clinical trial-level outcomes. The program converts trial protocols into daily patient care through four connected steps.

1. Patient selection. Age Well ATL screens candidates for a BMI of 30 or higher, or 27 or higher with comorbidities. Physicians review each patient’s full medical history, including prior weight-loss attempts, and complete contraindication screening before prescribing GLP-1 weight-loss therapy.

2. Individualized treatment planning. Each plan pairs GLP-1 pharmacotherapy with at least 150 minutes per week of moderate exercise and calorie-adjusted dietary guidance. Physicians shape these plans around personal circumstances and health needs, and the Atlanta clinic program deliverables document what each enrolled patient receives.

3. Regular follow-up. Scheduled visits drive dosage titration, progress monitoring, and lifestyle adherence support. This cadence keeps the trial conditions that produced strong outcomes intact inside everyday life.

4. Sustained maintenance. Discontinuation of GLP-1 therapy without a maintained lifestyle foundation results in substantial weight regain in the majority of patients. That finding makes Age Well ATL’s behavioral support component as clinically important as the pharmacotherapy itself, and it is why the comprehensive program framing carries real clinical meaning.

Physician oversight. Dr. Cassandra B. Donnelly, DO, leads the program with more than 30 years of experience in emergency medicine and osteopathic medicine. She earned her degree from Rowan University, completed her emergency medicine residency at Rutgers, and holds contributions in the National Library of Medicine. Patients in Atlanta, GA can reach Age Well ATL at 404-287-0123 to discuss enrollment.

Sources

Secret Link
Call 404-287-0123
Call 404-287-0123